Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
James LarkinVanna Chiarion-SileniRene GonzalezJean-Jacques GrobPiotr RutkowskiChristopher D LaoC Lance CoweyDirk SchadendorfJohn WagstaffReinhard DummerPier F FerrucciMichael SmylieDavid HoggAndrew HillIvan Márquez-RodasJohn HaanenMassimo GuidoboniMichele MaioPatrick SchöffskiMatteo S CarlinoCéleste LebbéGrant McArthurPaolo A AsciertoGregory A DanielsGeorgina V LongLars BastholtJasmine I RizzoAgnes BaloghAndriy MoshykF Stephen HodiJedd D WolchokPublished in: The New England journal of medicine (2019)
Among patients with advanced melanoma, sustained long-term overall survival at 5 years was observed in a greater percentage of patients who received nivolumab plus ipilimumab or nivolumab alone than in those who received ipilimumab alone, with no apparent loss of quality of life in the patients who received regimens containing nivolumab. (Funded by Bristol-Myers Squibb and others; CheckMate 067 ClinicalTrials.gov number, NCT01844505.).